Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients

Abstract Background Up to now, there are no clinically available minimally invasive biomarkers to accurately identify mild cognitive impairment (MCI) patients who are at greater risk to progress to Alzheimer’s disease (AD) dementia. The recent advent of blood-based markers opens the door for more ac...

Full description

Bibliographic Details
Main Authors: Alexa Pichet Binette, Sebastian Palmqvist, Divya Bali, Gill Farrar, Christopher J. Buckley, David A. Wolk, Henrik Zetterberg, Kaj Blennow, Shorena Janelidze, Oskar Hansson
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Alzheimer’s Research & Therapy
Subjects:
Plasma biomarkers
Alzheimer’s disease
p-tau
Mild cognitive impairment
Dementia
Online Access:https://doi.org/10.1186/s13195-022-00990-0

Internet

https://doi.org/10.1186/s13195-022-00990-0

Similar Items